ABCELLERA BIOLOGICS INC's ticker is ABCL and the CUSIP is 00288U106. A total of 85 filers reported holding ABCELLERA BIOLOGICS INC in Q1 2021. The put-call ratio across all filers is 0.68 and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2024 | $20,599,337 | -21.2% | 4,547,315 | -0.7% | 0.02% | -20.0% |
| Q4 2023 | $26,141,808 | +24.3% | 4,578,250 | +0.1% | 0.02% | +19.0% |
| Q3 2023 | $21,035,694 | -28.8% | 4,572,977 | -0.0% | 0.02% | -27.6% |
| Q2 2023 | $29,551,826 | -14.9% | 4,574,586 | -0.7% | 0.03% | -17.1% |
| Q1 2023 | $34,745,526 | -16.4% | 4,608,160 | +12.4% | 0.04% | -20.5% |
| Q4 2022 | $41,538,014 | +2.4% | 4,100,495 | -0.0% | 0.04% | -2.2% |
| Q3 2022 | $40,564,000 | +46.8% | 4,101,471 | +58.1% | 0.04% | +55.2% |
| Q2 2022 | $27,625,000 | +6.7% | 2,593,958 | -2.3% | 0.03% | +31.8% |
| Q1 2022 | $25,884,000 | -31.2% | 2,654,714 | +0.9% | 0.02% | +10.0% |
| Q4 2021 | $37,631,000 | -33.0% | 2,631,525 | -6.1% | 0.02% | -35.5% |
| Q3 2021 | $56,160,000 | -3.2% | 2,802,411 | +6.3% | 0.03% | 0.0% |
| Q2 2021 | $57,987,000 | -24.8% | 2,635,773 | +16.1% | 0.03% | -20.5% |
| Q1 2021 | $77,116,000 | – | 2,270,800 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Founders Fund VII Management, LLC | 3,773,530 | $28,452,416 | 91.13% |
| Founders Fund Growth Management, LLC | 407,017 | $3,068,908 | 14.23% |
| Gruss & Co., LLC | 167,500 | $1,262,950 | 7.99% |
| HARVARD MANAGEMENT CO INC | 4,105,095 | $30,952,416 | 3.25% |
| Belmont Capital, LLC | 510,000 | $3,845,400 | 3.18% |
| Prosight Management, LP | 753,528 | $5,681,601 | 2.69% |
| Intellectus Partners, LLC | 872,483 | $6,578,520 | 2.08% |
| Casdin Capital, LLC | 2,520,000 | $19,000,800 | 1.56% |
| GUARDIAN CAPITAL ADVISORS LP | 1,786,414 | $13,022,958 | 1.50% |
| Orbimed Advisors | 4,180,768 | $31,522,991 | 0.62% |